Recro Pharma, Inc. 4
4 · Recro Pharma, Inc. · Filed May 23, 2016
Insider Transaction Report
Form 4
LUDOMIRSKI ABRAHAM
Director
Transactions
- Sale
Common Stock
2015-11-24$9.01/sh−691$6,223→ 788,847 total(indirect: By SCP Vitalife Partners (Israel) II, L.P.) - Sale
Common Stock
2016-05-19$6.46/sh−1,252$8,083→ 783,642 total(indirect: By SCP Vitalife Partners (Israel) II, L.P.) - Sale
Common Stock
2016-05-20$6.45/sh−14,992$96,770→ 2,330,321 total(indirect: By SCP Vitalife Partners II LP) - Sale
Common Stock
2016-05-20$6.45/sh−5,008$32,326→ 778,634 total(indirect: By SCP Vitalife Partners (Israel) II, L.P.) - Sale
Common Stock
2015-11-24$9.01/sh−2,068$18,624→ 2,360,896 total(indirect: By SCP Vitalife Partners II LP) - Sale
Common Stock
2015-11-25$9.00/sh−4,648$41,832→ 2,356,248 total(indirect: By SCP Vitalife Partners II LP) - Sale
Common Stock
2015-11-27$9.00/sh−6,737$60,639→ 2,349,511 total(indirect: By SCP Vitalife Partners II LP) - Sale
Common Stock
2015-11-30$9.00/sh−450$4,050→ 2,349,061 total(indirect: By SCP Vitalife Partners II, L.P.) - Sale
Common Stock
2015-11-30$9.00/sh−150$1,350→ 784,894 total(indirect: By SCP Vitalife Partners (Israel) II, L.P.) - Sale
Common Stock
2016-05-19$6.46/sh−3,748$24,197→ 2,345,313 total(indirect: By SCP Vitalife Partners II LP) - Sale
Common Stock
2015-11-23$9.00/sh−11,082$99,748→ 2,362,964 total(indirect: By SCP Vitalife Partners II LP) - Sale
Common Stock
2015-11-23$9.00/sh−3,702$33,321→ 789,538 total(indirect: By SCP Vitalife Partners (Israel) II, L.P.) - Sale
Common Stock
2015-11-25$9.00/sh−1,553$13,977→ 787,294 total(indirect: By SCP Vitalife Partners (Israel) II, L.P.) - Sale
Common Stock
2015-11-27$9.00/sh−2,250$20,252→ 785,044 total(indirect: By SCP Vitalife Partners (Israel) II, L.P.)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.05, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.07, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.59, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.58, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 5 to this Form 4.